CA
EWTX icon

Clearstead Advisors’s Edgewise Therapeutics EWTX Stock Holding History

Clearstead Advisors’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$122 Buy
+3
New +$103 ﹤0.01% 3318
2025
Q4 		– Sell
-4
Closed -$65 – 2908
2025
Q3 		$65 Buy
+4
New +$57 ﹤0.01% 2957

Other funds holding EWTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PCM
Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return

Clearstead Advisors's EWTX Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Edgewise Therapeutics (EWTX) in Q2 2026: 3 shares worth $122. The stake represents ﹤0.01% of the portfolio and ranks #3318 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in EWTX as recently as Q3 2025.

Clearstead Advisors first reported a position in EWTX in Q3 2025 and has held it in 2 quarters since. 64 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Clearstead Advisors held 3 shares of Edgewise Therapeutics worth $122 as of Q2 2026.
  • Edgewise Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • Edgewise Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3318 holding.
  • Clearstead Advisors first reported a position in Edgewise Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 64 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.